J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.40.

"We talk about the S-curve for technology and in the past we've said it can be 10 or 20 years before you reach the top. I think what's going to be really different about AI is that time frame is going ...

UBS analyst Jo Walton maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of p1,580.00. The ...

Shares of GSK PLC GSK inched up 0.94% to £14.01 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the FTSE 100 Index UKX rising 0.28% to 8,557.81. GSK ...

On the second anniversary of her daughter Lisa Marie Presley’s sudden death at age 54, Priscilla Presley posted a heartfelt ...

Henry Schein (HSIC) stock in focus as KKR (KKR) builds stake and the company posts its preliminary Q4 2024 financials. Read ...

Zentalis Pharmaceuticals, Inc.’s ZNTL share price has dipped by 21.25%, which has investors questioning if this is right time ...

World’s First “Universal” Robotics Software Platform BOW Raises £4 Million Seed to Reduce Cost and Complexity of Programming ...

The Centers for Disease Control and Prevention abruptly ordered its staff to cease all collaboration with the World Health ...

Three recent big-ticket M&A deals have raised expectations the global biotech sector is recovering from its two-year slump.

The biggest risers on the FTSE 100 were British American Tobacco, up 142p to 3,150p, ConvaTec, up 9p to 248.4p, GSK, up 45.5p ...